VANCOUVER, BC / ACCESS Newswire / February 12, 2025 / Alset AI Ventures Inc.(TSXV:GPUS)(OTC:ALSCF)(FSE:1R60, WKN:A3ESVQ)("Alset AI" or the "Company") an artificial intelligence (AI) venture company advancing innovation through strategic investment and cloud computing solutions, announces the appointment of Jaret Christopher as a strategic advisor. Mr. Christopher brings a wealth of entrepreneurial experience in particular in the technology sector, and will provide strategic advisory and business development services to enhance the Company's AI ecosystem.

Growth Investor Pro's Alex King shares why hedging is crucial in volatile markets; using QQQ and PSQ ETFs to protect your portfolio. Mastering a charting method like Elliott Waves and Fibonacci is essential for recognizing patterns and predicting price movements.

Company to host a webcast t oday at 8:30 a.m. Eastern Time

Experience the W56 208” extended wheelbase step van at the Work Truck Week Ride & Drive, showcasing its road-tested durability.

Achieved statistical significance on primary endpoint at Week 12 on mean change from baseline DAS-28 CRP across all rosnilimab doses vs. placebo Achieved statistical significance on key secondary endpoints at Week 12 on ACR20, ACR50 and CDAI LDA Demonstrated highest ever reported responses on key secondary endpoints at Week 14 on ACR20, ACR50, ACR70 and CDAI LDA 69% of rosnilimab-treated patients achieved CDAI LDA at Week 14 and appear to show sustained CDAI LDA and ACR50 responses and potentially deepening ACR70 responses out to Week 28 Robust pharmacological activity observed in reduction of PD-1high T cells, increase in total Tregs …

Yesterday's announcement about including Firefly Neuroscience in the Nvidia Connect program further broadens Nvidia's extensive ecosystem and enhances its growth potential in the $10 trillion healthcare market. Nvidia's robust R&D spending and strong balance sheet ensure it stays way ahead of the main competitor, AMD, which is struggling with inventory and uncertain AI revenue growth prospects. AI tailwinds, including major projects like OpenAI's Stargate and positive news from Europe, reinforce Nvidia's growth prospects.

Generated Record Quarterly Revenue of $85 Million, a 35% Annual Increase Generated Record Quarterly Revenue of $85 Million, a 35% Annual Increase

NEW YORK, NY / ACCESS Newswire / February 12, 2025 / If you suffered a loss on your Innovative Industrial Properties, Inc. (NYSE:IIPR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/innovative-industrial-properties-inc-lawsuit-submission-form?prid=128899&wire=1 or contact Joseph E. Levi, Esq.

CARDIFF, UK / ACCESS Newswire / February 12, 2025 / Biodexa Pharmaceuticals PLC. (NASDAQ:BDRX), a clinical-stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, received Fast Track status from the U.S. Food and Drug Administration for eRapa, a proprietary encapsulated form of rapamycin being developed for the treatment of familial adenomatous polyposis (FAP).

Collaboration will combine AbbVie's oncology expertise and Xilio's proprietary tumor-activation technology to develop novel immunotherapies, including masked T-cell engagers Xilio to host investor conference call and webcast today at 8:30 am EST NORTH CHICAGO, Ill. and WALTHAM, Mass.

ATLANTA , Feb. 12, 2025 /PRNewswire/ -- The Board of Directors of Southern Company today announced the election of James O. (Jimmy) Etheredge as an independent director, effective Apr. 1, 2025.

NEW YORK, NY / ACCESS Newswire / February 12, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRTX) concerning possible violations of federal securities laws. On December 19, 2024, the company reported disappointing results from its RewinD-LB Phase 2b clinical trial for the pain drug suzetrigine.

Alcohol is generally inelastic as prices rise; demand tends to remain the same. However, this doesn't mean consumers can't trade down or switch types of alcohol.

All-in-one dive computer and smartwatch adds a bright AMOLED display for easy reading at any depth plus tools for life in and out of the water OLATHE, Kan. , Feb. 12, 2025 /PRNewswire/ -- Garmin (NYSE: GRMN) today announced the Descent™ G2 , a rugged watch-style dive computer with features to help divers explore both their underwater and topside worlds.

Phase III trial to assess the efficacy and safety of EscharEx ® for debridement and facilitation of active wound closure

Dubai and Islamabad, February 12 2025: VEON Ltd. (Nasdaq: VEON), a global digital operator (“VEON” or the “Group”), today announces that it has been shortlisted for two Global Mobile (GLOMO) Awards at the upcoming MWC 2025.

Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 Patients SHIELD II Enroll ed more than 7 00 P atients to D ate; Enrollment Completion Expected in March 202 5 , with T op- L ine Results Anticipated in Second Quarter of 2025 Company Completed Private Placement of Up to $41 Million; Proceeds and Exercise of Data-Triggered Warrant s Expected to Extend Cash Runway Beyond Potential NDA Approval Conference Call S cheduled for Today at 8:30 AM ET PETACH TIKVA, Israel, Feb. 12, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” …

BOCA RATON, Fla, Feb. 12, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology and inflammation company, continues to advance its Natural Killer (NK) cell therapy, INKmune™, in a Phase I/II trial (the “CaRe PC” trial) for men with metastatic castration-resistant prostate cancer (mCRPC). The Company is pleased to announce completion of the third and highest dose cohort of the Phase I portion of the trial allowing opening of the Phase II high dose cohort.

New York, NY, Feb. 12, 2025 (GLOBE NEWSWIRE) -- FOURTH QUARTER Total revenue, including billable expenses, was $2.9 billion Revenue before billable expenses ("net revenue") was $2.4 billion, with organic decrease of -1.8% Reported net income was $344.5 million Adjusted EBITA before restructuring charges and deal costs was $591.2 million with margin of 24.3% on revenue before billable expenses Diluted earnings per share of $0.92 as reported and $1.11 as adjusted FULL YEAR Total revenue, including billable expenses, was $10.7 billion Revenue before billable expenses ("net revenue") was $9.2 billion, with organic growth of 0.2% Reported net income was $689.5 …

TUS+VEN+AZA triplet achieves Cycle 1 complete remission (CR) in TP53-mutated/CK AML TUS+VEN+AZA triplet achieves Cycle 1 complete remissions in FLT3-wildtype AML patients TUS+VEN+AZA triplet shows favorable safety with no alteration of VEN and AZA dosing PK levels of TUS in the triplet remain equivalent to levels as TUS or TUS+VEN therapy SAN DIEGO and TORONTO, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company, today reported promising early safety and response results from newly diagnosed acute myeloid leukemia (AML) patients dosed in Aptose's Phase 1/2 TUSCANY trial …